Alimera Sciences announces Canadian regulatory approval for Iluvien

Alimera Sciences

26 November 2018 - Alimera Sciences today announced that Health Canada has approved Iluvien for the treatment of diabetic macular oedema. 

Iluvien is a fluocinolone acetonide sustained release intra-vitreal implant approved in the U.S. to treat DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intra-ocular pressure. Alimera signed an exclusive Canadian agreement for Iluvien with Knight Therapeutics in July 2015.

With the approval of Iluvien by Health Canada, Knight will now begin working with public and private payors to seek reimbursement for Iluvien, so that it can make Iluvien available to Canadian patients.

Read Alimera Sciences press release

Michael Wonder

Posted by:

Michael Wonder